Industry
Biotechnology
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Loading...
Open
15.00
Mkt cap
184M
Volume
233K
High
15.20
P/E Ratio
-3.20
52-wk high
61.90
Low
14.85
Div yield
N/A
52-wk low
5.09
Portfolio Pulse from Benzinga Insights
October 23, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Insights
October 09, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 08, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 02, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 01, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
September 25, 2024 | 8:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.